文献速递心律失常血脂与心血管预防

非奈利酮降低慢性肾脏病合并2型糖尿病患者新发心房颤动

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
PubMed 文献 · J Am Coll Cardiol · 2021-05-17

FIDELIO-DKD 研究预设分析显示,在慢性肾脏病合并 2 型糖尿病患者中,非奈利酮组新发心房颤动或扑动(AFF)发生率为 3.2%,安慰剂组为 4.5%,风险比 0.71(95%CI 0.53-0.94;p=0.016);且基线 AFF 病史不影响非奈利酮对肾脏和心血管结局的效益。

要点

  • 非奈利酮显著降低 CKD 合并 T2D 患者新发 AFF 风险(HR 0.71)。
  • 基线 AFF 病史不影响非奈利酮对肾脏及心血管结局的获益。
  • 非奈利酮组新发 AFF 82 例(3.2%),安慰剂组 117 例(4.5%)。

核心结论

  • 在 CKD 合并 T2D 患者中,非奈利酮降低新发 AFF 风险,且无论基线有无 AFF 病史,肾脏或心血管事件风险均降低。

研究设计与样本

  • FIDELIO-DKD 研究为随机、双盲、安慰剂对照、平行组、多中心、事件驱动的 III 期试验,患者按 1:1 随机接受非奈利酮或安慰剂。
  • 共纳入 5,674 例 CKD 合并 T2D 患者,尿白蛋白/肌酐比值 ≥30 至 ≤5,000 mg/g,eGFR ≥25 至 <75 ml/min/1.73 m²,并接受优化剂量的肾素-血管紧张素系统阻断剂治疗。
  • 新发 AFF 为预设结局,由独立心脏病专家委员会裁定。

主要发现

  • 全部 5,674 例患者中,461 例(8.1%)有 AFF 病史。
  • 新发 AFF 在非奈利酮组发生 82 例(3.2%),安慰剂组 117 例(4.5%),HR 0.71(95%CI 0.53-0.94;p=0.016)。
  • 基线 AFF 病史对非奈利酮在主要复合肾脏结局及关键次要心血管结局上的效应无显著影响(交互作用 p 值分别为 0.16 和 0.85)。

临床怎么用

  • 对于 CKD 合并 T2D 且已接受优化 RAS 阻断治疗的患者,可考虑使用非奈利酮以降低新发 AFF 风险。
  • 无论患者基线有无 AFF 病史,非奈利酮对肾脏和心血管结局的获益一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models. OBJECTIVES: This work aims to examine the effect of finerenone on new-onset AFF and cardiorenal effects by history of AFF in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) study. METHODS: Patients with CKD and T2D were randomized (1:1) to finerenone or placebo. Eligible patients had a urine albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g, an estimated glomerular filtration rate (eGFR) ≥25 to <75 ml/min/1.73 m2 and received optimized doses of renin-angiotensin system blockade. Effect on new-onset AFF was evaluated as a pre-specified outcome adjudicated by an independent cardiologist committee. The primary composite outcome (time to first onset of kidney failure, a sustained decrease of ≥40% in eGFR from baseline, or death from renal causes) and key secondary outcome (time to first onset of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) were analyzed by history of AFF. RESULTS: Of 5,674 patients, 461 (8.1%) had a history of AFF. New-onset AFF occurred in 82 (3.2%) patients on finerenone and 117 (4.5%) patients on placebo (hazard ratio: 0.71; 95% confidence interval: 0.53-0.94; p = 0.016). The effect of finerenone on primary and key secondary kidney and cardiovascular outcomes was not significantly impacted by baseline AFF (interaction p value: 0.16 and 0.85, respectively). CONCLUSIONS: In patients with CKD and T2D, finerenone reduced the risk of new-onset AFF. The risk of kidney or cardiovascular events was reduced irrespective of history of AFF at baseline. (EudraCT 2015-000990-11 [A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease]; Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease [FIDELIO-DKD]; NCT02540993).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Filippatos G, Bakris GL, Pitt B, et al. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021. PMID: 34015478. doi:10.1016/j.jacc.2021.04.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。